<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617782</url>
  </required_header>
  <id_info>
    <org_study_id>CL-P-20003</org_study_id>
    <nct_id>NCT04617782</nct_id>
  </id_info>
  <brief_title>Crossover Pharmacokinetic (PK) Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, 3-Period, Randomized, Crossover Pharmacokinetic Study to Evaluate the Steady-State Pharmacokinetics of 5 mg and 10 mg Corplex™ Donepezil Transdermal Delivery Systems Compared to 10 mg Oral Administration of Aricept® in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corium, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corium, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, open-label, randomized, 3-period, 3-treatment, crossover pharmacokinetic study to&#xD;
      evaluate the steady-state pharmacokinetics of 5 mg/day and 10 mg/day Corplex™ Donepezil TDS&#xD;
      manufactured with the commercial process compared to 10 mg Aricept® in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening Period:&#xD;
&#xD;
      Subjects will undergo a Screening Period up to 28 days prior to entering the Treatment Phase.&#xD;
&#xD;
      Treatment Phase consisting of 3 Treatment periods with 3 Treatments A, B, C.&#xD;
&#xD;
      Treatment Period 1: All Subjects will receive Treatment A; 5 mg/day Donepezil Transdermal&#xD;
      Delivery System (TDS); 1-week wear and applied for 5 consecutive weeks.&#xD;
&#xD;
      Treatment Periods 2 and 3: Subjects will be randomized (by gender) to receive either&#xD;
      sequences of Treatments B-C or Treatments C-B.&#xD;
&#xD;
      Treatment B: 10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks&#xD;
      Treatment C: 10 mg/day Aricept® donepezil tablet administered daily (QD) for 5 weeks.&#xD;
&#xD;
      Blood samples for pharmacokinetics and safety assessments will be collected during the&#xD;
      Treatment Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">April 5, 2021</completion_date>
  <primary_completion_date type="Actual">April 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Phase 1, open-label, randomized, 3-period, 3-treatment, crossover PK study to evaluate the steady-state pharmacokinetics</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Steady State Bioequivalence of 10 mg/day donepezil</measure>
    <time_frame>35 days of Treatment of each comparator</time_frame>
    <description>To evaluate steady-state donepezil plasma exposure following once-weekly treatments with 10 mg/day Corplex™ Donepezil TDS compared to once-daily oral administration of 10 mg Aricept®</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/day Donepezil Transdermal Delivery System (TDS) 1-week wear and applied weekly for 5 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/day Donepezil TDS 1-week wear and applied weekly for 5 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/day Aricept® donepezil tablet administered QD for 5 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Donepezil TDS</intervention_name>
    <description>Transdermal Delivery System</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept</intervention_name>
    <description>Oral</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females.&#xD;
&#xD;
          -  Subject's Body Mass Index (BMI) must be between 18 and 32 kg/m2 (inclusive).&#xD;
&#xD;
          -  Subject must be continuous non-smokers.&#xD;
&#xD;
          -  Subject must have a Fitzpatrick skin type of I, II or III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease or any other condition that, in the&#xD;
             opinion of the Investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
          -  After resting seated for at least 3 minutes, subjects should be excluded from the&#xD;
             study with the following vital signs at Screening&#xD;
&#xD;
               1. systolic blood pressure outside the range of 90-145 mmHg, or&#xD;
&#xD;
               2. diastolic blood pressure outside the range of 50-90 mmHg, or&#xD;
&#xD;
               3. resting heart rate outside the range of 40-100 beats per minute.&#xD;
&#xD;
          -  Has an isolated ALT ≥1.5x the ULN or AST ≥1.5x the ULN at Screening; or both ALT and&#xD;
             AST exceeding the ULN.&#xD;
&#xD;
          -  Estimated creatinine clearance at screening &lt;70 mL/min/1.73 m2.&#xD;
&#xD;
          -  Prolonged corrected QTcF on screening ECG (≥450 ms for both females and males).&#xD;
&#xD;
          -  History or presence of excessive hairy skin on application sites as deemed by the&#xD;
             Investigator to potentially interfere with patch adhesion or drug absorption.&#xD;
&#xD;
          -  History or presence of significant skin damage, diffuse skin diseases-, scars, tattoos&#xD;
             on the application sites or other skin disturbances as deemed by the Investigator to&#xD;
             potentially interfere with drug absorption or skin tolerability assessments&#xD;
&#xD;
          -  Use of donepezil hydrochloride or related drugs within 60 days prior to the first&#xD;
             study drug administration.&#xD;
&#xD;
          -  Has participated in another clinical trial within 30 days prior to Day -1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donepezil, Transdermal Delivery System</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

